Worth reading
69In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Deterioration
Direction inferred from the company’s description.Scale
-39.4
Year-on-year revenue growth (%)Wording
Conditional
How definitive the wording is.Contents of this document
Earnings presentationThird quarter of the fiscal year ending June 202610 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥10,663 million-39.4%
Operating profit¥3,509 million-62.4%
Ordinary income¥3,344 million-64.0%
Net income¥2,443 million-63.2%
Gross Profit Margin66.0%
Operating profit margin32.9%
Results for the three months of the current quarter
Net Sales
¥2,386 million-57.6%
Operating profit
¥257 million-90.8%
Revenue by major product
Standalone COVID-19 test kit
¥404 million-44.2%
COVID-19/influenza combo testing kits
¥805 million-74.4%
Influenza test kit
¥642 million-45.3%
Other
¥533 million
Full-year earnings forecast
Net Sales
¥15,048 million
Operating profit
¥4,368 million
Ordinary income
¥4,127 million
Profit for the period
¥5,692 million
Progress against full-year forecast 通期の予想に対して、いまどこまで進んだかの割合です。
Net Sales70.9%
Operating profit80.3%
Ordinary income81.0%
Profit for the period42.9%
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
Net Sales
COVID-19 volume factor¥-1,737 million
Combo volume factor¥-3,089 million
Influenza volume factor¥-674 million
Price-related factors for all products¥-1,097 million
Other¥-346 million
Operating profit
Decrease in COVID-19 revenue¥-1,617 million
Decrease in combo revenue¥-2,657 million
Decrease in influenza revenue¥-625 million
Cost changes for all products¥-545 million
Other¥-374 million
New initiatives
- The Mt. Fuji Mishima Plant began full-scale operations in February 2026
- An improved version of the COVID-19/influenza combo testing kit is scheduled to launch in the next fiscal year
Key KPIsA metric the company considers important as a management benchmark.
- Domestic antigen testing kit market size (standalone COVID-19)Approximately 30% lower year on year
- Domestic antigen testing kit market size (influenza)Approximately 20% higher year on year
- Domestic antigen testing kit market size (combo)Broadly in line with the year-earlier period
- Researchers on staff47 People
- Antigen testing development experience30 Years or more
- Inventory at the end of Q3¥3,607 million
Unit price and quantity metricsThese figures show sales broken down by price and volume.
The company discloses the factors behind changes in sales volume and selling prices. The price-related factor for all products was ▲¥1,097 million.Market Size / Share
The domestic infectious disease antigen testing market for medical institutions totaled 51.14 million tests in March 2026
Share
Influenza43%, No. 1 of 15 companies
Adenovirus32%, No. 1 of 10 companies
COVID-1942%, No. 1 of 19 companies
COVID-19/influenza combo19%, No. 3 of 18 companies
Number of stores and locations
Number of locations at period end4
LocationHead office and Kamishima Plant, Mt. Fuji Mishima Plant, Shimizucho Office and R&D Center, Tokyo Office
Changes during the periodThe Mt. Fuji Mishima Plant began full-scale operations in February 2026
Number of employees
Number of Employees382 People
Record date31 March 2026
Capital expenditures
¥6,340 million ¥6.34 billion
Annual Dividend
¥28 per share
Interim14
End of period14
Payout ratio
Not disclosed. A progressive dividend policy starting at ¥28 has been introduced| Item | Details |
|---|---|
| Document type | Earnings presentation |
| Fiscal Period Covered | Third quarter of the fiscal year ending June 2026 |
| Net Sales | ¥10,663 million (YoY -39.4%) |
| Operating profit | ¥3,509 million (YoY -62.4%) |
| Ordinary income | ¥3,344 million (YoY -64.0%) |
| Net income | ¥2,443 million (YoY -63.2%) |
| Gross Profit Margin | 66.0% |
| Operating profit margin | 32.9% |
| Results for the three months of the current quarter | Net Sales ¥2,386 million (YoY -57.6%) / Operating profit ¥257 million (YoY -90.8%) / Revenue by major product Standalone COVID-19 test kit ¥404 million (YoY -44.2%) / COVID-19/influenza combo testing kits ¥805 million (YoY -74.4%) / Influenza test kit ¥642 million (YoY -45.3%) / Other ¥533 million |
| Full-year earnings forecast | Net Sales ¥15,048 million / Operating profit ¥4,368 million / Ordinary income ¥4,127 million / Profit for the period ¥5,692 million |
| Progress against full-year forecast | Net Sales 70.9% / Operating profit 80.3% / Ordinary income 81.0% / Profit for the period 42.9% |
| Breakdown of Factors Affecting the Change | Net Sales COVID-19 volume factor ¥-1,737 million / Combo volume factor ¥-3,089 million / Influenza volume factor ¥-674 million / Price-related factors for all products ¥-1,097 million / Other ¥-346 million / Operating profit Decrease in COVID-19 revenue ¥-1,617 million / Decrease in combo revenue ¥-2,657 million / Decrease in influenza revenue ¥-625 million / Cost changes for all products ¥-545 million / Other ¥-374 million |
| Key KPIs | Indicator name Domestic antigen testing kit market size (standalone COVID-19) / Value Approximately 30% lower year on year, Indicator name Domestic antigen testing kit market size (influenza) / Value Approximately 20% higher year on year, Indicator name Domestic antigen testing kit market size (combo) / Value Broadly in line with the year-earlier period, Indicator name Researchers on staff / Value 47 People, Indicator name Antigen testing development experience / Value 30 Years or more, Indicator name Inventory at the end of Q3 / Value ¥3,607 million |
| Unit price and quantity metrics | The company discloses the factors behind changes in sales volume and selling prices. The price-related factor for all products was ▲¥1,097 million. |
| Number of stores and locations | Number of locations at period end 4 / Location Head office and Kamishima Plant, Mt. Fuji Mishima Plant, Shimizucho Office and R&D Center, Tokyo Office / Changes during the period The Mt. Fuji Mishima Plant began full-scale operations in February 2026 |
| Number of employees | Number of Employees 382 People / Record date 31 March 2026 |
| Annual Dividend | ¥28 per share |
| Payout ratio | Not disclosed. A progressive dividend policy starting at ¥28 has been introduced |
| Capital expenditures | ¥6,340 million (¥6.34 billion) |
| Market Size / Share | Market Size The domestic infectious disease antigen testing market for medical institutions totaled 51.14 million tests in March 2026 / Share Influenza 43%, No. 1 of 15 companies / Adenovirus 32%, No. 1 of 10 companies / COVID-19 42%, No. 1 of 19 companies / COVID-19/influenza combo 19%, No. 3 of 18 companies |
| New initiatives | The Mt. Fuji Mishima Plant began full-scale operations in February 2026, An improved version of the COVID-19/influenza combo testing kit is scheduled to launch in the next fiscal year |
Items this document does not state (10)
Selling, general and administrative expensesSelf-assessment against the planSegment resultsAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAcquisition of treasury sharesOrders received and order backlogKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The domestic market for standalone COVID-19 antigen testing kits contracted, wholesalers reduced inventories built up in the market during the year-earlier period, and sales volumes declined for both standalone COVID-19 and COVID-19/influenza combo testing kits. In Q3 alone, higher staffing costs and depreciation also weighed on operating profit.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.